{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:44:30Z","timestamp":1791945870323,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001663","name":"Volkswagen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9-Universit\u00e4tsmedizin Berlin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.yebeh.2015.11.009","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T05:08:31Z","timestamp":1450415311000},"page":"150-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Specific adverse effects of antiepileptic drugs \u2014 A true-to-life monotherapy study"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9963-8113","authenticated-orcid":false,"given":"Alexander B.","family":"Kowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Weissinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Gaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Fidzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Losch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Holtkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2015.11.009_bb0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1528-1157.1997.tb01128.x","article-title":"Quality of life of people with epilepsy: a European study","volume":"38","author":"Baker","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1212\/WNL.62.1.23","article-title":"Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial","volume":"62","author":"Gilliam","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0015","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1212\/01.wnl.0000345667.45642.61","article-title":"Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy","volume":"72","author":"Perucca","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1212\/WNL.0b013e318207b073","article-title":"Adverse antiepileptic drug effects in new-onset seizures: a case\u2013control study","volume":"76","author":"Perucca","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0030","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.seizure.2012.06.013","article-title":"Self reported adverse effects of mono and polytherapy for epilepsy","volume":"21","author":"Andrew","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0035","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1528-1167.2010.02520.x","article-title":"Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy","volume":"51","author":"Canevini","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.yebeh.2011.08.005","article-title":"Are adverse effects of antiepileptic drugs different in symptomatic partial and idiopathic generalized epilepsies? The Portuguese\u2013Brazilian validation of the Liverpool Adverse Events Profile","volume":"22","author":"Martins","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0045","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0050","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0404.2011.01488.x","article-title":"Self-reported symptoms in patients on antiepileptic drugs in monotherapy","volume":"124","author":"Wieshmann","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0055","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.yebeh.2011.01.010","article-title":"What is the role of depressive symptoms among other predictors of quality of life in people with well-controlled epilepsy on monotherapy?","volume":"20","author":"Kwon","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0060","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1528-1157.1994.tb02479.x","article-title":"Development of a novel scale to assess life fulfillment as part of the further refinement of a quality-of-life model for epilepsy","volume":"35","author":"Baker","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0065","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0070","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1026\/0012-1924.50.4.171","article-title":"Screening psychischer St\u00f6rungen mit dem \u201cGesundheitsfragebogen f\u00fcr Patienten (PHQ-D)\u201d","volume":"50","author":"Gr\u00e4fe","year":"2004","journal-title":"Diagnostica"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0080","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1006\/ebeh.2001.0170","article-title":"Psychometric properties of the German translation of the QOLIE-31","volume":"2","author":"May","year":"2001","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0085","author":"Wissenschaftlichen Institut der AOK (WIdO) des AOK-Bundesverbandes GbR"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0090","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.yebeh.2008.11.016","article-title":"Validation of the Spanish version of the Liverpool Adverse Events Profile in patients with epilepsy","volume":"15","author":"Carreno","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eplepsyres.2011.01.008","article-title":"Validation of the Chinese version of the Liverpool Adverse Events Profile in patients with epilepsy","volume":"94","author":"Chen","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0100","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/01.WNL.0000078031.32904.0D","article-title":"Psychiatric adverse events during levetiracetam therapy","volume":"61","author":"Mula","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0105","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.yebeh.2008.07.012","article-title":"The effects of levetiracetam on cognition: a non-interventional surveillance study","volume":"13","author":"Helmstaedter","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0110","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3988\/jcn.2011.7.3.128","article-title":"Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapy","volume":"7","author":"Lee","year":"2011","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002564","article-title":"Self-reported feelings of anger and aggression towards others in patients on levetiracetam: data from the UK antiepileptic drug register","volume":"3","author":"Wieshmann","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0120","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/jnnp-2011-300376","article-title":"KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy","volume":"84","author":"Trinka","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0125","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/00207454.2013.866951","article-title":"The adverse effects profile of levetiracetam in epilepsy: a more detailed look","volume":"124","author":"Mbizvo","year":"2014","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0130","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0135","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jocn.2011.09.032","article-title":"The acute effects of levetiracetam on nocturnal sleep and daytime sleepiness in patients with partial epilepsy","volume":"19","author":"Zhou","year":"2012","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1528-1167.2006.00376.x","article-title":"Effects of levetiracetam on nocturnal sleep and daytime vigilance in healthy volunteers","volume":"47","author":"Cicolin","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0145","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1474-4422(11)70154-5","article-title":"Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial","volume":"10","author":"Kwan","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0150","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/jnnp-2011-301999","article-title":"The LaLiMo trial: lamotrigine compared with levetiracetam in the initial 26weeks of monotherapy for focal and generalised epilepsy \u2014 an open-label, prospective, randomised controlled multicenter study","volume":"83","author":"Rosenow","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0155","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0160","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0165","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.seizure.2005.09.011","article-title":"The LAM-SAFE study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults","volume":"14","author":"Steinhoff","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0170","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2015.11.009_bb0175","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1528-1167.2006.00956.x","article-title":"The Liverpool Adverse Events Profile: relation to AED use and mood","volume":"48","author":"Panelli","year":"2007","journal-title":"Epilepsia"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505015006228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505015006228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T17:00:01Z","timestamp":1537117201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505015006228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":35,"alternative-id":["S1525505015006228"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2015.11.009","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specific adverse effects of antiepileptic drugs \u2014 A true-to-life monotherapy study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2015.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}